DSDavid R. M. Smith

David R. M. Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David R. M. Smith has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Koen Bernardus Pouwels

    Nuffield Department of Medicine, University of Oxford

    12 shared publications
  • Lulla Opatowski

    Epidemiology and Modelling of Antibiotic Evasion, Institut Pasteur, Université de Paris, Paris, France; Centre for Epidemiology and Population Health, Anti-infective Evasion and Pharmacoepidemiology team, Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Institut national de la santé et de la recherche médicale, Montigny-Le-Bretonneux, France

    9 shared publications
  • Laura Temime

    PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France; Modélisation, Épidémiologie et Surveillance des Risques Sanitaires, Conservatoire national des arts et métiers, Paris, France

    8 shared publications
  • F. Christiaan K. Dolk

    Modelling and Economics Unit, National Infection Service, Public Health England, London, UK

    6 shared publications
  • Laura Temime

    Laboratoire Modélisation, Epidémiologie et Surveillance des Risques Sanitaires, Conservatoire National des Arts et Métiers

    6 shared publications
  • Audrey Duval

    Univ Paris Cite, Inst Pasteur, Epidemiol & Modelling Antibiot Evas, Paris, France

    5 shared publications

Latest Publications

  • Mathematical modelling and simulation of the transmission, surveillance and control of human pathogens in healthcare settings

    by David Smith

    Modélisation mathématique et simulation de la transmission, la surveillance et le contrôle des agents pathogènes dans les milieux de soins: Les infections associées aux soins sont le résultat de la dissémination d’une grande diversité de microorganismes pathogènes. Elles représentent un fardeau important de morbidité et de mortalité dans le monde. L’objectif principal de cette thèse était de développer de nouveaux modèles mathématiques afin de mieux comprendre les dynamiques de transmission des pathogènes dans ces milieux spécifiques et de proposer des mesures de contrôle et de surveillance adaptées. Je me suis spécifiquement intéressé aux bactéries résistantes aux antibiotiques et à SARS-CoV-2. Dans un premier temps, un nouveau cadre de modélisation pour l’épidémiologie des bactéries résistantes aux antibiotiques a été formalisé. Celui-ci prend en compte des mécanismes d’interactions intra-hôtes entre le microbiote humain et des bactéries pathogènes, tel que la résistance à la colonisation et le transfert horizontal des gènes de résistance. La prise en compte de ces interactions permet d’expliquer comment un niveau de consommation intermédiaire d’antibiotiques maximise la sélection et la propagation des bactéries résistantes au niveau populationnel. Ce modèle a ensuite été appliqué à différentes espèces bactériennes pour évaluer l’impact potentiel d’interventions de santé publique sur le risque qui est leur est associé. Les résultats des simulations suggèrent une efficacité des mesures barrières pour prévenir la dissémination de Staphylococcus aureus résistant à la méticilline. En revanche, celles-ci se sont avérées inefficaces en ce qui concerne les Entérobactéries multirésistantes. A l’inverse, les politiques antibiotiques, mais également les interventions ciblant la préservation du microbiote, étaient globalement efficace pour prévenir toutes les espèces pathogènes prises en compte. Dans un second temps, j’ai analysé les simulations issues d’un modèle individu-centré pour investiguer comment les stratégies de surveillance pouvaient être optimisées afin de détecter et contrôler au mieux des épidémies de SARS-CoV- 2 dans les hôpitaux de long séjour. Dans un contexte de pandémie précoce où l’accès aux tests était limité, les résultats ont montré l’intérêt du déploiement du dépistage de groupe, qui s’est avéré être la stratégie la plus efficace pour détecter des épidémies. Dans un contexte de pandémie ultérieur, j’ai montré l’intérêt du déploiement additionnel de stratégies de dépistage par des tests antigéniques et mis en évidence l’importance des délais entre les tests. Ainsi, par le développement de modèles spécifiques, les travaux de cette thèse ont permis de mieux comprendre l’influence du microbiote sur le risque de transmission nosocomiale des bactéries multirésistantes dans les milieux de soin. Ils ont également permis de proposer des protocoles de surveillance optimisés pour détecter précocement et contrôler la dissémination de SARS-CoV-2 dans les milieux de long séjour dans un contexte de ressources sanitaires limitées.

  • Open Access

    Effects of the COVID-19 pandemic on antibiotic use and resistance in French hospitals, 2019–22: a retrospective ecological analysis of national surveillance data

    by Maylis Layan, David R M Smith, Solen Kernéis, Loïc Simon, Catherine Dumartin, Lory Dugravot, Amélie Jouzeau, Fanny Chereau, Sylvie Maugat, Laetitia Gambotti, et al.


  • Open Access

    Advancing monitoring of antimicrobial resistance trajectories using flexible spatiotemporal modelling: a change-point analysis

    by Kasim Allel, David R. M. Smith, Nam Nguyen, Samuel Lipworth, Koen B. Pouwels

    Background Detecting changes in infectious disease trends, including antimicrobial resistance (AMR), is critical for developing effective public health strategies and surveillance systems. However, many statistical methods struggle to detect gradual shifts as they primarily rely on mean-level shift estimates. Methods We examined AMR prevalence among Enterobacterales isolates, primarily carbapenem-resistance (CRE), in bloodstream and urinary tract infections from 24 European countries and 45 US-states (2004–2022) leveraging Pfizer’s ATLAS dataset. We applied spatiotemporal generalised additive models (GAMs) with intrinsic Gaussian Markov Random Fields to estimate AMR prevalence and included country/state-time interactions. We used restricted maximum likelihood to estimate AMR prevalence growth rates and their corresponding first derivatives (increase/decrease rate) and second derivatives (acceleration/deceleration rate), which were used to identify change-points marking significant trend shifts in AMR dynamics. We performed biological sex and age-group-specific GAMs, and evaluated the association between growth rates and carbapenem usage. Carbapenem use was obtained from the European surveillance of antimicrobial consumption Network. Results We observed a consistent increase in CRE prevalence over time in Europe and the US. In Europe, the rate of change increased in 2007 (first-derivative change-point), with deceleration in 2012 and 2019 and acceleration in 2015 (second-derivative change-points), followed by a decline in 2020 (first-derivative change-point), particularly in Central and Eastern Europe, including France as an exemplar. Conversely, the US showed fewer change-points, with New York (exemplar) marking a substantial acceleration change-point after 2008. Subgroup analyses showed that population change points were largely driven by males over 18, reflecting both their larger numbers and more pronounced, often earlier, shifts. We found a positive association between carbapenem use and CRE growth rates in Europe. Conclusions Employing GAMs could improve AMR surveillance by detecting changes in trends in the overall population and subgroups, while evaluating the impact of intervention strategies.

  • Open Access

    Health-economic burden of chikungunya infection and potential cost-effectiveness of preventive vaccination in 31 countries

    by Junwen Zhou, Natasha Salant, Hale-Seda Radoykova, Janey Messina, William Wint, Joshua Longbottom, Katherine M Holohan, Katelyn A Dinkel, Mira L T Sytsma, Andrew A Torkelson, et al.

    As the first chikungunya vaccines become available, estimates of their cost-effectiveness are needed. We developed a modelling framework to project the health-economic burden of chikungunya across 31 countries. We simulated several preventive vaccination campaigns and estimated threshold vaccination costs as the cumulative societal costs averted per vaccine dose. From 2025 to 2050, we projected a cumulative 5.96 million (5.10 million-6.93 million) DALYs and $76.5 billion ($57.4 billion-$95.7 billion) societal costs. A five-year population-wide campaign targeting 50% of individuals aged ≥12 years, followed by a ten-year annual routine adolescent vaccination programme, averted 681,000 (569,000-802,000) DALYs and $11.8 billion ($8.73 billion-$14.9 billion) societal costs. Standalone population-wide campaigns were the most cost-effective, with threshold vaccination costs ranging from $1.11 ($0.77-$1.44) in the Democratic Republic of Congo to $48.1 ($36.0-$60.3) in Panama. Preventive deployment of a chikungunya vaccine with a favourable safety profile could substantially reduce the future burden of chikungunya across endemic settings.


  • Open Access

    Advancing monitoring of antimicrobial resistance trajectories using flexible spatiotemporal modelling: a change-point analysis

    by Kasim Allel, David R. M. Smith, Nam Nguyen, Samuel Lipworth, Koen B. Pouwels

    Background Detecting changes in infectious disease trends, including antimicrobial resistance (AMR), is critical for developing effective public health strategies and surveillance systems. However, many statistical methods struggle to detect gradual shifts as they primarily rely on mean-level shift estimates. Methods We examined AMR prevalence among Enterobacterales isolates, primarily carbapenem-resistance (CRE), in bloodstream and urinary tract infections from 24 European countries and 45 US-states (2004-2022) leveraging Pfizer’s ATLAS dataset. We applied spatiotemporal generalised additive models (GAMs) with intrinsic Gaussian Markov Random Fields to estimate AMR prevalence and included country/state-time interactions. We used restricted maximum likelihood to estimate AMR prevalence growth rates and their corresponding first derivatives (increase/decrease rate) and second derivatives (acceleration/deceleration rate), which were used to identify change-points marking significant trend shifts in AMR dynamics. We performed biological sex and age-group-specific GAMs, and evaluated the association between growth rates and carbapenem usage. Carbapenem use was obtained from the European surveillance of antimicrobial consumption Network. Results We observed a consistent increase in CRE prevalence over time in Europe and the US. In Europe, the rate of change increased in 2007 (first-derivative change-point), with deceleration in 2012 and 2019 and acceleration in 2015 (second-derivative change-points), followed by a decline in 2020 (first-derivative change-point), particularly in Central and Eastern Europe, including France as an exemplar. Conversely, the US showed fewer change-points, with New York (exemplar) marking a substantial acceleration change-point after 2008. Subgroup analyses showed that population change points were largely driven by males over 18, reflecting both their larger numbers and more pronounced, often earlier, shifts. We found a positive association between carbapenem use and CRE growth rates in Europe. Conclusions Employing GAMs could improve AMR surveillance by detecting changes in trends in the overall population as well as in subgroups.

  • Open Access

    Health-economic impacts of age- and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia and Sierra Leone: a modelling study

    by David R M Smith, Mary Chriselda Antony Oliver, Katherine M Holohan, Harry R Street, Andrew A Torkelson, Danny Asogun, Oladele Oluwafemi Ayodeji, Benedict N Azuogu, Anton Camacho, William A Fischer, et al.

    Introduction: Lassa fever is an emerging zoonotic disease endemic to West Africa. Several vaccines aimed at preventing Lassa fever are currently under development, creating a need to assess how best to administer them once licensed for human use. Methods: We developed a mathematical model using a zoonosis risk map and epidemiological data from recent and ongoing cohort studies to predict the health-economic burden of Lassa fever across age and sex groups in endemic regions. We simulated vaccination campaigns targeting different risk groups to estimate the health-economic benefits of various scenarios for Lassa vaccine administration. Threshold vaccine costs (TVCs) were estimated in International dollars (I$ 2023), accounting for healthcare costs, productivity losses and monetised disability-adjusted life-years (DALYs) averted due to vaccination. Results: The most efficient strategy for preventing symptomatic Lassa fever was targeting children aged 2-14, for preventing hospitalisation was targeting adolescents and adults aged 15-49, for preventing death was targeting older adults aged 50+, and for preventing DALYs was targeting women of childbearing age (WCBA) aged 15-49. Under base case assumptions, the highest TVC for a single-dose vaccine was estimated at I$7.39 (95% uncertainty interval (UI): I$4.33-I$11.60) when targeting adolescents and adults, followed by I$6.69 (95%UI: I$4.17-I$9.85) when targeting older adults, I$6.10 (95%UI: I$3.56-I$9.74) when targeting WCBA and I$1.94 (95%UI: I$1.10-I$3.10) when targeting children. Conclusion: These results suggest that the most cost-efficient use of limited doses of Lassa fever vaccine is to target adolescents and adults followed by the elderly.


  • Open Access

    Impacts of the COVID-19 pandemic on antibiotic use and resistance in hospitals: a retrospective ecological analysis of French national surveillance data over 2019-2022

    by Maylis Layan, David R M Smith, Solen Kernéis, Loïc Simon, Catherine Dumartin, Lory Dugravot, Amélie Jouzeau, Sylvie Maugat, Laetitia Gambotti, Laurence Watier, et al.

    Summary: Background: The COVID-19 pandemic led to major disruptions in healthcare services at the hospital and community levels. The resulting impact on antibiotic resistance (ABR) in hospitals is difficult to predict. Methods: We exploited data from the French national surveillance system over four years (2019-2022) including 414 hospitals across 12 French regions. We evaluated changes in annual antibiotic use compared to 2019 using multiple comparison tests. We also compiled a large dataset of 692,551 incident isolates for five antibiotic-bacterium pairs. Using negative binomial regression models accounting for autocorrelation and antibiotic use, we evaluated associations between resistant isolates incidence and COVID-19 indicators (pandemic periods or intubated COVID-19 patient prevalence). We investigated how these associations varied specifically in ICUs ( n =85) and across geographical regions. Findings: The use of some antibiotics, including azithromycin, imipenem and meropenem, significantly increased between 2020 and 2022. Concomitantly, the incidence of methicillin-resistant Staphylococcus aureus (up to 37%, 95% CI: 18-53%) and ESBL-producing Escherichia coli (up to 33%, 95% CI: 16-46%) isolates significantly decreased in hospitals and ICUs during the pandemic. A transient decrease in ICUs was also observed for ESBL-producing Klebsiella pneumoniae during periods of strong anti-COVID-19 interventions in the community (24%, 95% CI: 6-38%). No significant changes for ESBL-producing Enterobacter cloacae complex were observed. Very interestingly, the incidence of carbapenem-resistant Pseudomonas aeruginosa isolates was associated with COVID-19 intubation prevalence in hospitals (pP. aeruginosa to all tested antibiotics in 2022 compared to 2017, using point prevalence survey results. Conversely, one study focusing on US Veterans Affairs hospitals showed increased incidence and resistance of healthcare-associated carbapenem-resistant P. aeruginosa (CR-PA) infections during the pandemic. Most studies used univariate statistical approaches. Only two studies included COVID-19-related variables in their models; they found no association with MRSA or extended-spectrum cephalosporin-resistant E. coli and K. pneumoniae . Added value of this study: Here, we provide the first evaluation of the impact of the pandemic on antibiotic consumption and resistance for five antibiotic-bacterium pairs (MRSA, CR-PA, ESBL-producing E. coli , ESBL-producing K. pneumoniae , and ESBL-producing E. cloacae complex) in hospitals, at the national and regional scales. By analyzing French surveillance data from the SPARES database including 414 hospitals that represent up to 14% of French hospitals, we evaluated annual changes in antibiotic use and quantified the impacts at the weekly level of the COVID-19 pandemic on the incidence of five of the most prevalent resistant bacteria in France. Accounting for autocorrelation and antibiotic use, factors that were not considered in previous studies, we report a significant positive association between the weekly incidence of CR-PA isolates and the prevalence of intubated COVID-19 patients in the preceding weeks. Carbapenem use and intubation being risk factors of CR-PA infections, our results suggest a direct impact of the pandemic on CR-PA epidemiology. Inversely, we show that the incidence of ESBL-producing E. coli and MRSA isolates decreased after the start of the first pandemic wave at the hospital level but also in ICUs. The fine grain analysis across 12 French administrative regions revealed regional heterogeneities, but highlighted consistent associations in the regions most affected by the COVID-19 pandemic. Implications of all the available evidence: Pandemics not only destabilize healthcare systems by adding pressure and changing healthcare worker behaviors, but also influence the epidemiology of other infectious diseases as shown in our study. We specifically highlight the contrasting effects of the COVID-19 pandemic on ABR in French hospitals, associated with an increase in CR-PA isolate incidence but a general decrease in ESBL-producing E. coli and MRSA. This work highlights how national-scale hospital surveillance systems such as SPARES that collect data at the weekly level are key to capture the evolving impacts of pandemics. They also allow to generate hypotheses on the potential mechanisms of action of the pandemic on ABR epidemiology, as showcased by the analysis of CR-PA isolates incidence, and thereby participate in the improvement of healthcare systems in pandemic context.

  • Open Access

    Health and economic impacts of Lassa vaccination campaigns in West Africa

    by David R. M. Smith, Joanne Turner, Patrick Fahr, Lauren A. Attfield, Paul R. Bessell, Christl A. Donnelly, Rory Gibb, Kate E. Jones, David W. Redding, Danny Asogun, et al.

    Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as having pandemic potential. This study estimates the health-economic burden of Lassa fever throughout West Africa and projects impacts of a series of vaccination campaigns. We also model the emergence of ‘Lassa-X’—a hypothetical pandemic Lassa virus variant—and project impacts of achieving 100 Days Mission vaccination targets. Our model predicted 2.7 million (95% uncertainty interval: 2.1–3.4 million) Lassa virus infections annually, resulting over 10 years in 2.0 million (793,800–3.9 million) disability-adjusted life years (DALYs). The most effective vaccination strategy was a population-wide preventive campaign primarily targeting WHO-classified ‘endemic’ districts. Under conservative vaccine efficacy assumptions, this campaign averted $20.1 million ($8.2–$39.0 million) in lost DALY value and $128.2 million ($67.2–$231.9 million) in societal costs (2021 international dollars ($)). Reactive vaccination in response to local outbreaks averted just one-tenth the health-economic burden of preventive campaigns. In the event of Lassa-X emerging, spreading throughout West Africa and causing approximately 1.2 million DALYs within 2 years, 100 Days Mission vaccination averted 22% of DALYs given a vaccine 70% effective against disease and 74% of DALYs given a vaccine 70% effective against both infection and disease. These findings suggest how vaccination could alleviate Lassa fever’s burden and assist in pandemic preparedness.


  • Open Access

    Predicting consequences of COVID-19 control measure de-escalation on nosocomial transmission and mortality: a modelling study in a French rehabilitation hospital

    by David R.M. Smith, Audrey Duval, Rebecca Grant, Mohamed Abbas, Stephan Harbarth, Lulla Opatowski, Laura Temime


  • Open Access

    Health and economic impacts of Lassa vaccination campaigns in West Africa

    by David R M Smith, Joanne Turner, Patrick Fahr, Lauren A Attfield, Paul R Bessell, Christl A Donnelly, Rory Gibb, Kate E Jones, David W Redding, Danny Asogun, et al.

    Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as having pandemic potential. This study estimates the health-economic burden of Lassa fever throughout West Africa and projects impacts of a series of vaccination campaigns. We also model the emergence of “Lassa-X” – a hypothetical pandemic Lassa virus variant – and project impacts of achieving 100 Days Mission vaccination targets. Our model predicted 2.7M (95% uncertainty interval: 2.1M-3.4M) Lassa virus infections annually, resulting over ten years in 2.0M (793.8K-3.9M) disability-adjusted life years (DALYs). The most effective vaccination strategy was a population-wide preventive campaign primarily targeting WHO-classified “endemic” districts. Under conservative vaccine efficacy assumptions, this campaign averted $20.1M ($8.2M-$39.0M) in lost DALY value and $128.2M ($67.2M-$231.9M) in societal costs (International dollars 2021). Reactive vaccination in response to local outbreaks averted just one-tenth the health-economic burden of preventive campaigns. In the event of Lassa-X emerging, spreading throughout West Africa and causing approximately 1.2M DALYs within two years, 100 Days Mission vaccination averted 22% of DALYs given a vaccine 70% effective against disease, and 74% of DALYs given a vaccine 70% effective against both infection and disease. These findings suggest how vaccination could alleviate Lassa fever’s burden and assist in pandemic preparedness.